참고문헌
- Kris MG, Natale RB, Herbst RS, Lynch TJ Jr, Prager D, Belani CP, et al. Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: a randomized trial. Jama 2003;290:2149-58. https://doi.org/10.1001/jama.290.16.2149
- Perez-Soler R. Phase II clinical trial data with the epidermal growth factor receptor tyrosine kinase inhibitor erlotinib (OSI-774) in non-small-cell lung cancer. Clin Lung Cancer 2004;6 Suppl 1:S20-3. https://doi.org/10.3816/CLC.2004.s.010
- Jackman D, Pao W, Riely GJ, Engelman JA, Kris MG, Janne PA, et al. Clinical definition of acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in nonsmall- cell lung cancer. J Clin Oncol 2010;28:357-60. https://doi.org/10.1200/JCO.2009.24.7049
- Oxnard GR, Arcila ME, Chmielecki J, Ladanyi M, Miller VA, Pao W. New strategies in overcoming acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in lung cancer. Clin Cancer Res 2011;17:5530-7. https://doi.org/10.1158/1078-0432.CCR-10-2571
- Kobayashi S, Boggon TJ, Dayaram T, Janne PA, Kocher O, Meyerson M, et al. EGFR mutation and resistance of nonsmall- cell lung cancer to gefitinib. N Engl J Med 2005;352:786-92 https://doi.org/10.1056/NEJMoa044238
- Pao W, Miller VA, Politi KA, Riely GJ, Somwar R, Zakowski MF, et al. Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain. PLoS Med 2005;2:e73. https://doi.org/10.1371/journal.pmed.0020073
- Kwak EL, Sordella R, Bell DW, Godin-Heymann N, Okimoto RA, Brannigan BW, et al. Irreversible inhibitors of the EGF receptor may circumvent acquired resistance to gefitinib. Proc Natl Acad Sci U S A 2005;102:7665-70. https://doi.org/10.1073/pnas.0502860102
- Miller VA, Hirsh V, Cadranel J, Chen YM, Park K, Kim SW, et al. Afatinib versus placebo for patients with advanced, metastatic non-small-cell lung cancer after failure of erlotinib, gefitinib, or both, and one or two lines of chemotherapy (LUX-Lung 1): a phase 2b/3 randomised trial. Lancet Oncol 2012;13:528-38. https://doi.org/10.1016/S1470-2045(12)70087-6
- Zhou W, Ercan D, Chen L, Yun CH, Li D, Capelletti M, et al. Novel mutant-selective EGFR kinase inhibitors against EGFR T790M. Nature 2009;462:1070-4. https://doi.org/10.1038/nature08622
- Engelman JA, Zejnullahu K, Mitsudomi T, Song Y, Hyland C, Park JO, et al. MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling. Science 2007;316:1039-43. https://doi.org/10.1126/science.1141478
- Zhang Z, Lee JC, Lin L, Olivas V, Au V, LaFramboise T, et al. Activation of the AXL kinase causes resistance to EGFRtargeted therapy in lung cancer. Nat Genet 2012;44:852-60. https://doi.org/10.1038/ng.2330
- Sequist LV, Waltman BA, Dias-Santagata D, Digumarthy S, Turke AB, Fidias P, et al. Genotypic and histological evolution of lung cancers acquiring resistance to EGFR inhibitors. Sci Transl Med 2011;3:75ra26.
- Bean J, Brennan C, Shih JY, Riely G, Viale A, Wang L, et al. MET amplification occurs with or without T790M mutations in EGFR mutant lung tumors with acquired resistance to gefitinib or erlotinib. Proc Natl Acad Sci U S A 2007;104:20932-7. https://doi.org/10.1073/pnas.0710370104
- Morinaga R, Okamoto I, Furuta K, Kawano Y, Sekijima M, Dote K, et al. Sequential occurrence of non-small cell and small cell lung cancer with the same EGFR mutation. Lung Cancer 2007;58:411-3. https://doi.org/10.1016/j.lungcan.2007.05.014
- Rho JK, Choi YJ, Lee JK, Ryoo BY, Na, II, Yang SH, et al. Epithelial to mesenchymal transition derived from repeated exposure to gefitinib determines the sensitivity to EGFR inhibitors in A549, a non-small cell lung cancer cell line. Lung Cancer 2009;63:219-26. https://doi.org/10.1016/j.lungcan.2008.05.017
- Chung JH, Rho JK, Xu X, Lee JS, Yoon HI, Lee CT, et al. Clinical and molecular evidences of epithelial to mesenchymal transition in acquired resistance to EGFR-TKIs. Lung Cancer 2011;73:176-82. https://doi.org/10.1016/j.lungcan.2010.11.011
- Rho JK, Choi YJ, Lee JK, Ryoo BY, Na II, Yang SH, et al. The role of MET activation in determining the sensitivity to epidermal growth factor receptor tyrosine kinase inhibitors. Mol Cancer Res 2009;7:1736-43. https://doi.org/10.1158/1541-7786.MCR-08-0504
- Carmichael J, DeGraff WG, Gazdar AF, Minna JD, Mitchell JB. Evaluation of a tetrazolium-based semiautomated colorimetric assay: assessment of chemosensitivity testing. Cancer Res 1987;47:936-42.
- Rho JK, Choi YJ, Ryoo BY, Na II, Yang SH, Kim CH, et al. p53 enhances gefitinib-induced growth inhibition and apoptosis by regulation of Fas in non-small cell lung cancer. Cancer Res 2007;67:1163-9. https://doi.org/10.1158/0008-5472.CAN-06-2037
- Walker GE, Antoniono RJ, Ross HJ, Paisley TE, Oh Y. Neuroendocrine- like differentiation of non-small cell lung carcinoma cells: regulation by cAMP and the interaction of mac25/ IGFBP-rP1 and 25.1. Oncogene 2006;25:1943-54. https://doi.org/10.1038/sj.onc.1209213
- Byers LA, Wang J, Nilsson MB, Fujimoto J, Saintigny P, Yordy J, et al. Proteomic profiling identifies dysregulated pathways in small cell lung cancer and novel therapeutic targets including PARP1. Cancer Discov 2012;2:798-811. https://doi.org/10.1158/2159-8290.CD-12-0112
- Tanno S, Ohsaki Y, Nakanishi K, Toyoshima E, Kikuchi K. Small cell lung cancer cells express EGFR and tyrosine phosphorylation of EGFR is inhibited by gefitinib ("Iressa", ZD1839). Oncol Rep 2004;12:1053-7.
- Moore AM, Einhorn LH, Estes D, Govindan R, Axelson J, Vinson J, et al. Gefitinib in patients with chemo-sensitive and chemo-refractory relapsed small cell cancers: a Hoosier Oncology Group phase II trial. Lung Cancer 2006;52:93-7. https://doi.org/10.1016/j.lungcan.2005.12.002
- Okamoto I, Araki J, Suto R, Shimada M, Nakagawa K, Fukuoka M. EGFR mutation in gefitinib-responsive small-cell lung cancer. Ann Oncol 2006;17:1028-9. https://doi.org/10.1093/annonc/mdj114
- Zakowski MF, Ladanyi M, Kris MG; Memorial Sloan-Kettering Cancer Center Lung Cancer OncoGenome Group. EGFR mutations in small-cell lung cancers in patients who have never smoked. N Engl J Med 2006;355:213-5. https://doi.org/10.1056/NEJMc053610
- Sterlacci W, Fiegl M, Hilbe W, Auberger J, Mikuz G, Tzankov A. Clinical relevance of neuroendocrine differentiation in nonsmall cell lung cancer assessed by immunohistochemistry: a retrospective study on 405 surgically resected cases. Virchows Arch 2009;455:125-32. https://doi.org/10.1007/s00428-009-0812-0
- Carles J, Rosell R, Ariza A, Pellicer I, Sanchez JJ, Fernandez- Vasalo G, et al. Neuroendocrine differentiation as a prognostic factor in non-small cell lung cancer. Lung Cancer 1993;10:209-19. https://doi.org/10.1016/0169-5002(93)90181-V
- Graziano SL, Mazid R, Newman N, Tatum A, Oler A, Mortimer JA, et al. The use of neuroendocrine immunoperoxidase markers to predict chemotherapy response in patients with non-small-cell lung cancer. J Clin Oncol 1989;7:1398-406. https://doi.org/10.1200/JCO.1989.7.10.1398
- Gajra A, Tatum AH, Newman N, Gamble GP, Lichtenstein S, Rooney MT, et al. The predictive value of neuroendocrine markers and p53 for response to chemotherapy and survival in patients with advanced non-small cell lung cancer. Lung Cancer 2002;36:159-65. https://doi.org/10.1016/S0169-5002(01)00463-9
- Graziano SL, Kern JA, Herndon JE, Tatum A, Brisson ML, Memoli V, et al. Analysis of neuroendocrine markers, HER2 and CEA before and after chemotherapy in patients with stage IIIA non-small cell lung cancer: a Cancer and Leukemia Group B study. Lung Cancer 1998;21:203-11. https://doi.org/10.1016/S0169-5002(98)00063-4
- Schleusener JT, Tazelaar HD, Jung SH, Cha SS, Cera PJ, Myers JL, et al. Neuroendocrine differentiation is an independent prognostic factor in chemotherapy-treated nonsmall cell lung carcinoma. Cancer 1996;77:1284-91. https://doi.org/10.1002/(SICI)1097-0142(19960401)77:7<1284::AID-CNCR9>3.0.CO;2-I
피인용 문헌
- Transformation to Small Cell Lung Cancer as an Acquired Resistance Mechanism in EGFR-mutant Lung Adenocarcinoma: A Case Report of Complete Response to Etoposide and Cisplatin vol.101, pp.3, 2013, https://doi.org/10.5301/tj.5000276
- Histological transformation from non-small cell to small cell lung carcinoma after treatment with epidermal growth factor receptor-tyrosine kinase inhibitor vol.6, pp.6, 2013, https://doi.org/10.1111/1759-7714.12217
- 非小细胞肺癌EGFR-TKIs耐药——小细胞肺癌转化的研究进展 vol.20, pp.10, 2017, https://doi.org/10.3779/j.issn.1009-3419.2017.10.10
- Resistance to epithelial growth factor receptor tyrosine kinase inhibitors in a patient with transformation from lung adenocarcinoma to small cell lung cancer: A case report vol.14, pp.1, 2013, https://doi.org/10.3892/ol.2017.6229
- Histological transformation after acquired resistance to epidermal growth factor tyrosine kinase inhibitors vol.23, pp.2, 2018, https://doi.org/10.1007/s10147-017-1211-1
- Effect of A549 neuroendocrine differentiation on cytotoxic immune response vol.7, pp.5, 2018, https://doi.org/10.1530/ec-18-0145
- Ultrastructural changes associated to the neuroendocrine transdifferentiation of the lung adenocarcinoma cell line A549 vol.123, pp.8, 2021, https://doi.org/10.1016/j.acthis.2021.151797